TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23314784

Group type: EXPERIMENTAL
Intervention: Full stimulation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sub-perception stimulation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Overall patient outcomes
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Safety outcomes
Number of subjects: 32
Study: 21598188

Group type: EXPERIMENTAL
Intervention: Gain-framed message
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Present outcomes (gain, loss)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Absent outcomes (non-gain, non-loss)
Number of subjects: 0
Study: 18706464

Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Younger healthy controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 0
Study: 16968106

Group type: EXPERIMENTAL
Intervention: Flavonols derived from sea buckthorn ingested with oatmeal porridge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flavonols at two dosages in oatmeal porridge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sea buckthorn oil added to porridge
Number of subjects: 0
Study: 14573316

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (100 mg orally)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 11050369

Group type: EXPERIMENTAL
Intervention: Self Care intervention
Number of subjects: 226

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 226
Study: 9316439

Group type: EXPERIMENTAL
Intervention: IGF-I (10 micrograms.kg‐1.h‐1)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study: 8476616

Group type: EXPERIMENTAL
Intervention: Morphine 0.1 mg/kg added to axillary block solution (AX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline added to axillary block solution with morphine 0.1 mg/kg IV (CT)
Number of subjects: 0
Study: 3090830

Group type: EXPERIMENTAL
Intervention: Asparaginase (ASNase)
Number of subjects: 14

Group type: COMPARATOR
Intervention: High-dose cytosine arabinoside (HIDARAC)
Number of subjects: 14
Study: 29502640

Group type: EXPERIMENTAL
Intervention: Elaborated reminder prompt
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Simple reminder prompt
Number of subjects: 648

Group type: COMPARATOR
Intervention: Usual practice control
Number of subjects: 648
Study: 27441946

Group type: EXPERIMENTAL
Intervention: Anti-domestic violence ads with narrative exemplars promoting bystander awareness and intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-domestic violence ads without narrative exemplars featuring emotional self-efficacy appeal targeting bystanders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ads featuring a celebrity spokesperson
Number of subjects: 0
Study: 25362169

Group type: EXPERIMENTAL
Intervention: Amiodarone (AM)
Number of subjects: 31

Group type: COMPARATOR
Intervention: d-sotalol (DS)
Number of subjects: 31
Study: 23952897

Group type: EXPERIMENTAL
Intervention: Primary care buprenorphine OST
Number of subjects: 15

Group type: COMPARATOR
Intervention: Specialist facility buprenorphine OST
Number of subjects: 15

Group type: COMPARATOR
Intervention: Specialist facility methadone OST
Number of subjects: 15
Study: 20693725

Group type: EXPERIMENTAL
Intervention: Community engagement to activate a multiple-agency network
Number of subjects: 0

Group type: COMPARATOR
Intervention: Support for individual agencies to implement depression QI
Number of subjects: 0
Study: 18937675

Group type: EXPERIMENTAL
Intervention: Education programme delivered by trained peer advisers
Number of subjects: 83

Group type: COMPARATOR
Intervention: Education programme delivered by specialist health professionals
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 83

Group type: COMPARATOR
Intervention: Health professionals
Number of subjects: 83
Study: 16157900

Group type: COMPARATOR
Intervention: Mitoxantrone 12 mg/m2
Number of subjects: 194

Group type: COMPARATOR
Intervention: Mitoxantrone 5 mg/m2
Number of subjects: 194
Study: 14521770

Group type: EXPERIMENTAL
Intervention: Self-management program for hypertensive patients
Number of subjects: 0
Study: 10953829

Group type: EXPERIMENTAL
Intervention: Quadruple therapy (omeprazole, tetracycline, metronidazole, bismuth subcitrate) for 7 days followed by OCA7 if failure
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: OCA7 for 7 days followed by quadruple therapy if failure
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Cost per case treated
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Cost per case eradicated
Number of subjects: 97
Study: 8840836

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 768

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 768
Study: 1378147

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 6392353

Group type: EXPERIMENTAL
Intervention: Intramuscular levonantradol 0.5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intramuscular levonantradol 1.0 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intramuscular levonantradol 1.5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intramuscular levonantradol 2.0 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31059641

Group type: EXPERIMENTAL
Intervention: HTTRx (10 mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: HTTRx (30 mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: HTTRx (60 mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: HTTRx (90 mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: HTTRx (120 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 28578601

Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg twice daily)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Standard therapy (single-agent chemotherapy of physician's choice)
Number of subjects: 302
Study: 25835109

Group type: EXPERIMENTAL
Intervention: 5 µg ramosetron
Number of subjects: 12

Group type: COMPARATOR
Intervention: Test meal alone
Number of subjects: 12
Study: 24251677

Group type: EXPERIMENTAL
Intervention: Diabetes prevention program (7 interactive classes and behavioral support)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Enhanced standard care (2 interactive classes on diabetes prevention)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study: 22940687

Group type: COMPARATOR
Intervention: Control group (N=245)
Number of subjects: 245
Study: 19230737

Group type: EXPERIMENTAL
Intervention: Betaglucan-enriched bread (3g/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: White bread without betaglucan
Number of subjects: 46
Study: 17129592

Group type: COMPARATOR
Intervention: GSK albendazole
Number of subjects: 1277

Group type: COMPARATOR
Intervention: Royal Drug albendazole
Number of subjects: 1277

Group type: EXPERIMENTAL
Intervention: Curex albendazole
Number of subjects: 1277
Study: 14695734

Group type: EXPERIMENTAL
Intervention: Oral amantadine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 15892278

Group type: EXPERIMENTAL
Intervention: Gufusheng capsule (GFSC) combined with arthrectomy hip synovial membrane excision, femoral head decompression, and muscle-bone flap transplantation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Arthrectomy hip synovial membrane excision, femoral head decompression, and muscle-bone flap transplantation (Control)
Number of subjects: 45
Study: 10336032

Group type: EXPERIMENTAL
Intervention: Lateral tarsorrhaphy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Tight patching
Number of subjects: 36
Study: 8598699

Group type: EXPERIMENTAL
Intervention: Continued second-line therapy (n = 142)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo (n = 143)
Number of subjects: 285
Study: 1662127

Group type: EXPERIMENTAL
Intervention: Loading dose of 300 mg on the first day and 150 mg for the subsequent 5 days (Group 1)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Loading dose of 400 mg on the first day and 200 mg for the subsequent 5 days (Group 2)
Number of subjects: 23
Study: 6123123

Group type: EXPERIMENTAL
Intervention: 3 mg cloxazolam
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 5 mg diazepam
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 31375753

Group type: EXPERIMENTAL
Intervention: Modified Alternate-day Calorie Restriction (MACR)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Normal habitual diet (Control)
Number of subjects: 43
Study: 29645317

Group type: EXPERIMENTAL
Intervention: Slow infusion (SI) of low-dose ketamine (0.3 mg/kg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Intravenous push (IVP) of low-dose ketamine (0.3 mg/kg)
Number of subjects: 59
Study: 26781417

Group type: EXPERIMENTAL
Intervention: air+resveratrol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hyperoxia+resveratrol
Number of subjects: 0

Group type: COMPARATOR
Intervention: hyperoxia
Number of subjects: 0

Group type: COMPARATOR
Intervention: control
Number of subjects: 0
Study: 24213962

Group type: EXPERIMENTAL
Intervention: High-intensity blue light therapy (λmax = 465 nm, 84.8 µW/cm(2), 39.5 lux, 1.74 × 10(14) photons/cm(2)/s)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lower-intensity yellow light therapy (λmax = 574 nm, 18.5 µW/cm(2), 68 lux, 1.21 × 10(12) photons/cm(2)/s)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 30
Study: 22947842

Group type: EXPERIMENTAL
Intervention: Complete oral prophylaxis (periodontal therapy)
Number of subjects: 40
Study: 20660892

Group type: EXPERIMENTAL
Intervention: Thought suppression during Week 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thought expression during Week 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no thought suppression or expression) during Week 2
Number of subjects: 0
Study: 17986818

Group type: EXPERIMENTAL
Intervention: Short-term psychosocial intervention programme for family carers, including education about dementia and structured problem-solving in 6 group meetings.
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group received treatment as usual.
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Short-term psychosocial intervention programme for family carers.
Number of subjects: 180
Study: 16291984

Group type: EXPERIMENTAL
Intervention: Sildenafil 20 mg
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Sildenafil 40 mg
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Sildenafil 80 mg
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Sildenafil (one year treatment)
Number of subjects: 278
Study: 11889322

Group type: EXPERIMENTAL
Intervention: GIK solution (30% glucose in water with insulin 50 IU/L, and KCl 40 mM) at 1.5 mL/kg/hr for 24 hrs
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (normal saline) at 1.5 mL/kg/hr for 24 hrs
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (15 healthy volunteers with no heart disease)
Number of subjects: 20
Study: 11783297

Group type: EXPERIMENTAL
Intervention: Gandou I (GD)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Dimercaptosuccinate acid (DMSA)
Number of subjects: 94
Study: 7604142

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 31815542

Group type: EXPERIMENTAL
Intervention: Extravirgin olive oil consumption
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study: 28763898

Group type: EXPERIMENTAL
Intervention: Single lumen endobronchial tube (D group, n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Double lumen endobronchial tube (S group, n=30)
Number of subjects: 60
Study: 26140898

Group type: EXPERIMENTAL
Intervention: Simulator training (SIM)
Number of subjects: 19
Study: 24081996

Group type: EXPERIMENTAL
Intervention: Cigarette brand logo awareness
Number of subjects: 2423

Group type: EXPERIMENTAL
Intervention: Age and household tobacco use
Number of subjects: 2423
Study: 21591581

Group type: EXPERIMENTAL
Intervention: G-CSF (10 microg/kg body weight) for five consecutive days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo for five consecutive days
Number of subjects: 16
Study: 17389264

Group type: EXPERIMENTAL
Intervention: LVH[-] group
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: LVH[+] group
Number of subjects: 73

Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: LVH[-] and LVH[+] groups
Number of subjects: 73
Study: 15731121

Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1%
Number of subjects: 4186

Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.03%
Number of subjects: 4186

Group type: EXPERIMENTAL
Intervention: Topical pimecrolimus
Number of subjects: 4186

Group type: EXPERIMENTAL
Intervention: Topical pimecrolimus and tacrolimus
Number of subjects: 4186

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 4186
Study: 12018715

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (1 g IV for 3 days in weeks 1 and 2, 2 days in week 3, 1 day in week 4)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral prednisone (1.5 mg/kg/day for 4 weeks)
Number of subjects: 18
Study: 10638398

Group type: EXPERIMENTAL
Intervention: 2 mg DHEM/2% RAMEB nasal spray
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 2 mg DHEM/4 mg RAMEB nasal powder
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 2 mg Diergo nasal spray
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 2 mg DHEM solution p.o.
Number of subjects: 9

Group type: COMPARATOR
Intervention: i.m. administration of 0.5 mg DHEM
Number of subjects: 9
Study: 7501485

Group type: EXPERIMENTAL
Intervention: Special Care Unit (SCU)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Intensive Care Unit (ICU)
Number of subjects: 220
Study: 1904351

Group type: EXPERIMENTAL
Intervention: rtPA
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 6753183

Group type: EXPERIMENTAL
Intervention: Alcohol followed by fructose
Number of subjects: 10

Group type: COMPARATOR
Intervention: Alcohol followed by placebo
Number of subjects: 10
Study: 30696454

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 24

Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 24
Study: 30672233

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with Betastatin mesylate (12 mg, 3 times a day) and mecobalamin (0.5 mg, 3 times a day)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Simple western medication (Betastatin mesylate 12 mg, 3 times a day and mecobalamin 0.5 mg, 3 times a day)
Number of subjects: 96
Study: 27006007

Group type: EXPERIMENTAL
Intervention: Brief intervention for antenatal anxiety led by midwives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brief intervention for antenatal anxiety
Number of subjects: 0
Study: 25051294

Group type: EXPERIMENTAL
Intervention: Changes in salivary estradiol levels
Number of subjects: 62
Study: 23039913

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) group training
Number of subjects: 162
Study: 19830574

Group type: EXPERIMENTAL
Intervention: Transcranial dynamic magnetotherapy (TcDMT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Basal therapy
Number of subjects: 54
Study: 17646490

Group type: EXPERIMENTAL
Intervention: Modified form with improved readability and processability
Number of subjects: 190

Group type: COMPARATOR
Intervention: Standard form
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Modified form
Number of subjects: 190
Study: 16243716

Group type: EXPERIMENTAL
Intervention: Enzyme extract (900 mg) in three divided doses
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Enzyme therapy
Number of subjects: 21
Study: 11857598

Group type: EXPERIMENTAL
Intervention: 5-aminolaevulinic acid (ALA) 60 mg/kg BW, oral, 6-8 hours prior to PDT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Photosan 2 mg/kg BW, i.v., 48 hours before PDT
Number of subjects: 40
Study: 10459544

Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cyclosporine (CSA)
Number of subjects: 20
Study: 8520561

Group type: EXPERIMENTAL
Intervention: Chemotherapy (ChT) plus radiotherapy (RT)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Chemotherapy (ChT) alone
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Patients who achieved complete response (CR) after treatment
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Patients who achieved partial response (PR) after induction ChT
Number of subjects: 124
Study: 2215254

Group type: EXPERIMENTAL
Intervention: Aspartame-sweetened beverage (600 mg APM per serving)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Unsweetened beverage
Number of subjects: 6
Study: 77367

Group type: EXPERIMENTAL
Intervention: Oral cromoglycate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31842259

Group type: EXPERIMENTAL
Intervention: FunctionalHIIT
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 20
Study: 28746262

Group type: EXPERIMENTAL
Intervention: Intervention Arm I
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intervention Arm II
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study: 27473440

Group type: EXPERIMENTAL
Intervention: Structured lifestyle intervention over 12 months including individualized endurance training (minimum of 18 MET-h physical activity per week) and nutrition education based on the Mediterranean diet.
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual care (control group) receiving information regarding a healthy lifestyle.
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Structured lifestyle intervention group (IG) with monthly group training sessions and regular telephone contacts.
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (CG) receiving one general training session about healthy nutrition.
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Assessment at randomization and subsequent time points (3 and 12 months) using spiroergometry and validated questionnaires.
Number of subjects: 600
Study: 25162191

Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy (3 weeks, 6 sessions)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 80
Study: 22726532

Group type: EXPERIMENTAL
Intervention: MDFR + Text Messages + Dietary Feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDFR + Dietary Feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: MDFR, no feedback
Number of subjects: 0
Study: 20708570

Group type: EXPERIMENTAL
Intervention: Comprehensive classroom curriculum program, enhancements to school climate, improvements in care pathways, and community forums.
Number of subjects: 5633

Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 5633

Group type: EXPERIMENTAL
Intervention: Teacher-rated assessments of school climate.
Number of subjects: 5633
Study: 17482623

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg daily for 4 weeks, increasing to 45 mg for 12 weeks
Number of subjects: 22
Study: 16130888

Group type: EXPERIMENTAL
Intervention: Consulting physicians
Number of subjects: 3139

Group type: EXPERIMENTAL
Intervention: Taking OTC medication
Number of subjects: 3139

Group type: EXPERIMENTAL
Intervention: Doing nothing
Number of subjects: 3139

Group type: EXPERIMENTAL
Intervention: Having a family doctor and number of OTC medicines on hand
Number of subjects: 3139

Group type: EXPERIMENTAL
Intervention: Three or more kinds of OTC medicine
Number of subjects: 3139
Study: 12133625

Group type: EXPERIMENTAL
Intervention: Full-length tyrosinase protein vaccination
Number of subjects: 10
Study: 10074992

Group type: EXPERIMENTAL
Intervention: Doulas
Number of subjects: 314

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 314
Study: 7580778

Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO2) as an insufflating gas
Number of subjects: 139

Group type: COMPARATOR
Intervention: Conventional atmospheric air (AA)
Number of subjects: 139
Study: 2142756

Group type: EXPERIMENTAL
Intervention: Cuprophan membrane (CUP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Polyacrylonitrile membrane (AN 69)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Both membranes (CUP and AN 69)
Number of subjects: 24
Study: 7272675

Group type: EXPERIMENTAL
Intervention: 200 mg i.v. preoperatively
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: 600 mg i.v. preoperatively
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: 600 mg i.v. postoperatively
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: 200 mg i.v. preoperatively and 200 mg i.v. daily for 3 days postoperatively
Number of subjects: 196
Study: 31626831

Group type: EXPERIMENTAL
Intervention: Information designed to increase awareness of the risks of SSB consumption
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Information about SSB consumption norms
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Planning to reduce SSB consumption
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Risks information
Number of subjects: 430

Group type: COMPARATOR
Intervention: Control information
Number of subjects: 430

Group type: COMPARATOR
Intervention: No norms information
Number of subjects: 430

Group type: COMPARATOR
Intervention: Control planning task
Number of subjects: 430
Study: 29169877

Group type: EXPERIMENTAL
Intervention: Cetuximab plus carboplatin and paclitaxel with or without bevacizumab
Number of subjects: 1313

Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel with or without bevacizumab (control group)
Number of subjects: 1313

Group type: EXPERIMENTAL
Intervention: Cetuximab in EGFR FISH-positive squamous cell carcinoma
Number of subjects: 1313

Group type: COMPARATOR
Intervention: Control group in EGFR FISH-positive squamous cell carcinoma
Number of subjects: 1313

Group type: EXPERIMENTAL
Intervention: Cetuximab group adverse events
Number of subjects: 1313

Group type: COMPARATOR
Intervention: Control group adverse events
Number of subjects: 1313